<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071032</url>
  </required_header>
  <id_info>
    <org_study_id>159</org_study_id>
    <secondary_id>U01HL073958-06</secondary_id>
    <secondary_id>U01HL073958</secondary_id>
    <secondary_id>U01HL074815</secondary_id>
    <nct_id>NCT00071032</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare liberal red blood cell transfusion therapy with
      restrictive red blood cell transfusion therapy in surgical patients with cardiovascular
      disease or risk factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Red blood cell transfusions are an extremely common medical intervention in both the United
      States and worldwide; over 14 million units of blood are transfused in the United States.
      Between 60 and 70 percent of all blood is transfused in the surgical setting. Despite the
      common use of red blood cell transfusions, the threshold for transfusion has not been
      adequately evaluated and is very controversial. A decade ago, the standard of care was to
      administer a peri-operative transfusion whenever the hemoglobin (Hgb) level fell below 10
      g/dl (the &quot;10/30 rule&quot;). Concerns about the safety of blood, especially with respect to HIV
      and hepatitis, and the absence of data to support a 10 g/dl threshold led to the current
      standard of care, which is to administer blood transfusions based on the presence of
      symptoms, and not a specific Hgb/hematocrit level. However, there have not been any
      randomized clinical trials done with surgical patients that have tested the efficacy and
      safety of withholding blood until the patient develops symptoms, or the &quot;10/30&quot; approach to
      transfusion. Patients with underlying cardiovascular disease are at greatest risk of adverse
      effects from reduced Hgb levels.

      DESIGN NARRATIVE:

      This is a multi-center randomized trial to test the effectiveness of a transfusion strategy
      that maintains postoperative Hgb levels above 10 g/dl (liberal transfusion) in improving
      patient outcome. This will be compared to the restrictive (symptomatic) transfusion strategy
      in which blood transfusion is withheld until the patient develops symptoms of anemia or Hgb
      less than 8 g/dL. Participants will be randomly assigned to one of the two transfusion
      strategies. The liberal (10 g/dl) threshold strategy will use enough red blood cell units to
      maintain Hgb levels at or above 10 g/dl through hospital discharge. Restrictive (Symptomatic)
      transfusion strategy patients will receive red blood cell transfusions for symptoms of
      anemia, although transfusion is also permitted, but not required, if the Hgb level falls
      below 8 g/dl. Outcomes will include functional recovery (primary outcome: ability to walk 10
      feet across a room without human assistance or death 60 days post-randomization), lower
      extremity activities of daily living and instrumental activities of daily living, survival up
      to 60-days and long-term, disposition (i.e., nursing home placement), and postoperative
      complications (e.g., myocardial infarction, unstable angina, or death in hospital, pneumonia,
      wound infection, thromboembolism, stroke).

      Ambulation at 60 days is known to be highly predictive of ultimate functional outcome as well
      as of mortality at one year. Because inability to walk has such important implications for
      quality of life, and because it is a common problem, it far outweighs the small risk of viral
      infection or other complications from transfusion in elderly patients.

      The trial will also evaluate the effect of transfusion threshold on postoperative risk of
      acute cardiac ischemia. The strategy will be to enhance surveillance for ischemic events by
      increasing the number of EKG and serum troponin measurements beyond those already called for
      in the original FOCUS protocol.

      There is an ancillary study to the trial (R01 HL085706) to examine delirium as an outcome in
      a subsample of 139 patients. We will assess short-term (in hospital) and longer-term (after
      30 days) severity of delirium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>ascertained via telephone follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction, Unstable Angina, or Death for Any Reason</measure>
    <time_frame>In-hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications (e.g., Pneumonia, Wound Infection, Thromboembolism, Stroke)</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30-daym, 60- day and long term up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition Status (i.e., Nursing Home Placement)</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function (e.g., Lower Extremity Activities of Daily Living, Instrumental Activities of Daily Living, Fatigue/Energy)</measure>
    <time_frame>30 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in Hospital</measure>
    <time_frame>In-hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>In-hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Outcomes (a) Death, Myocardial Infarction, and Pneumonia and b) Death, Myocardial Infarction, Pneumonia, Thromboembolism and Stroke)</measure>
    <time_frame>In-hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2016</enrollment>
  <condition>Anemia</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Thromboembolism</condition>
  <condition>Pneumonia</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Liberal (10 g/dL) Transfusion Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liberal (10 g/dL) Transfusion Strategy</intervention_name>
    <description>This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.</description>
    <arm_group_label>Liberal (10 g/dL) Transfusion Strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Restrictive (Symptomatic) Transfusion Strategy</intervention_name>
    <description>Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has undergone surgical repair for a hip fracture

          -  Has a postoperative Hgb level below 10 g/dL within three days of surgery

          -  Diagnosis of cardiovascular disease (e.g., coronary artery disease, congestive heart
             failure, stroke or transient ischemic attack, or peripheral vascular disease) or
             cardiovascular risk factors (e.g., diabetes mellitus, hypertension,
             hypercholesterolemia, tobacco use, or creatinine levels greater than 2.0 mg/dL)

        Exclusion Criteria:

          -  Unable to walk prior to hip fracture

          -  Declines blood transfusions

          -  Suffered multiple traumas

          -  Pathologic fracture of the hip due to malignancy

          -  Clinically recognized acute myocardial infarction within the 30 days prior to study
             entry

          -  Previously participated in the trial and fractured the other hip

          -  Symptoms associated with anemia (e.g., ischemic chest pain) or actively bleeding at
             the time of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L. Carson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medicine &amp; Dentistry of NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Terrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medicine &amp; Dentistry of NJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D; FOCUS Investigators. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). Transfusion. 2006 Dec;46(12):2192-206. Review.</citation>
    <PMID>17176334</PMID>
  </reference>
  <results_reference>
    <citation>Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011 Dec 29;365(26):2453-62. doi: 10.1056/NEJMoa1012452. Epub 2011 Dec 14.</citation>
    <PMID>22168590</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2003</study_first_submitted>
  <study_first_submitted_qc>October 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2003</study_first_posted>
  <results_first_submitted>August 14, 2014</results_first_submitted>
  <results_first_submitted_qc>August 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <last_update_submitted>August 14, 2014</last_update_submitted>
  <last_update_submitted_qc>August 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>rwjmsmedicine</investigator_full_name>
    <investigator_title>Jeffrey L Carson</investigator_title>
  </responsible_party>
  <keyword>Blood Disease</keyword>
  <keyword>blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liberal (10 g/dL) Transfusion Strategy</title>
          <description>Transfusion strategy that maintains postoperative Hgb levels &gt;= 10 g/dL</description>
        </group>
        <group group_id="P2">
          <title>Restrictive Strategy</title>
          <description>Blood transfusion is withheld until the patient develops symptoms of anemia or at physician discretion of the hemoglobin level falls below 8 g/dL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1007"/>
                <participants group_id="P2" count="1009"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="998"/>
                <participants group_id="P2" count="1001"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Primary Outcome</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Liberal (10 g/dL) Transfusion Strategy</title>
          <description>Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
Liberal (10 g/dL) Transfusion Strategy: Maintains postoperative Hgb levels above 10 g/dL. This threshold strategy uses enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.</description>
        </group>
        <group group_id="B2">
          <title>Restrictive Strategy</title>
          <description>Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
Restrictive (Symptomatic) Transfusion Strategy: Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1007"/>
            <count group_id="B2" value="1009"/>
            <count group_id="B3" value="2016"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.8" spread="8.8"/>
                    <measurement group_id="B2" value="81.5" spread="9.0"/>
                    <measurement group_id="B3" value="81.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                    <measurement group_id="B2" value="770"/>
                    <measurement group_id="B3" value="1527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="609"/>
                    <measurement group_id="B2" value="613"/>
                    <measurement group_id="B3" value="1222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="398"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Disease</title>
          <description>History of coronary artery disease, congestive heart failure, cardiovascular disease, or peripheral vascular disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="637"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="1268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No History of Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death</title>
        <description>ascertained via telephone follow-up</description>
        <time_frame>60 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal (10 g/dL) Transfusion Strategy</title>
            <description>Transfusion strategy that maintains postoperative Hgb levels &gt;= 10 g/dL</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Strategy</title>
            <description>Blood transfusion is withheld until the patient develops symptoms of anemia or at physician discretion of the hemoglobin level falls below 8 g/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death</title>
          <description>ascertained via telephone follow-up</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="998"/>
                <count group_id="O2" value="1001"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351"/>
                    <measurement group_id="O2" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Liberal Arm (numerator) compared to Restrictive Arm (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction, Unstable Angina, or Death for Any Reason</title>
        <time_frame>In-hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal (10 g/dL) Transfusion Strategy</title>
            <description>Transfusion strategy that maintains postoperative Hgb levels &gt;= 10 g/dL</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Strategy</title>
            <description>Symptomatic transfusion strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia or at physician discretion of the hemoglobin level falls below 8 g/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction, Unstable Angina, or Death for Any Reason</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1005"/>
                <count group_id="O2" value="1008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Liberal Arm (numerator) compared to Restrictive Arm (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Complications (e.g., Pneumonia, Wound Infection, Thromboembolism, Stroke)</title>
        <time_frame>In hospital</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>30-daym, 60- day and long term up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition Status (i.e., Nursing Home Placement)</title>
        <time_frame>60 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Function (e.g., Lower Extremity Activities of Daily Living, Instrumental Activities of Daily Living, Fatigue/Energy)</title>
        <time_frame>30 and 60 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in Hospital</title>
        <time_frame>In-hospital</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <time_frame>In-hospital</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Outcomes (a) Death, Myocardial Infarction, and Pneumonia and b) Death, Myocardial Infarction, Pneumonia, Thromboembolism and Stroke)</title>
        <time_frame>In-hospital</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 60 days following randomization</time_frame>
      <desc>medical events were captured during hospitalization (up to 30 days); mortality was determined at 60 days</desc>
      <group_list>
        <group group_id="E1">
          <title>Liberal (10 g/dL) Transfusion Strategy</title>
          <description>Transfusion strategy that maintains post randomization Hgb levels &gt;= 10 g/dL</description>
        </group>
        <group group_id="E2">
          <title>Restrictive Strategy</title>
          <description>Symptomatic transfusion strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia or at physician discretion of the hemoglobin level falls below 8 g/dL</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>during hospitalization (up to 30 days)</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="1005"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1008"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <description>during hospitalization (up to 30 days)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1005"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1008"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <description>during hospitalization (up to 30 days)</description>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="1005"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="1007"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death at 60 days</sub_title>
                <description>Detected via telephone follow-up</description>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="998"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>during hospitalization (up to 30 days)</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1005"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1007"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey L Carson, MD</name_or_title>
      <organization>Rutgers Robert Wood Johnsom Medical School</organization>
      <phone>732-235-7122</phone>
      <email>Jeffrey.Carson@rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

